Highbridge Capital Management Reports New 5.2% Stake in Aspire Biopharma Holdings, Inc.

Highbridge Capital Management, LLC filed a Schedule 13G on May 15, 2026, reporting a new 5.2% ownership stake in Aspire Biopharma Holdings, Inc. (ASBP). As of the event date on March 31, 2026, the reporting person beneficially owns 273,000 shares of common stock. These shares are issuable upon the exercise of warrants held by various funds and accounts managed by Highbridge. The filing indicates that Highbridge holds sole voting and dispositive power over the reported 273,000 shares. The percentage calculation is based on approximately 5,024,124 shares of common stock outstanding as of March 27, 2026, as reported in the company's most recent annual report. Highbridge Capital Management, a Delaware limited liability company, is acting as an investment adviser and certified that the securities were acquired in the ordinary course of business without the intent to influence or change the control of the issuer. This filing represents an initial reporting of a significant holding by Highbridge in the biopharmaceutical company.